{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:15Z","timestamp":1788441375694,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has changed the therapeutic approach to advanced gastric cancer (AGC) and has shown survival benefits compared with standard chemotherapy. However, in clinical practice, its use remains heterogeneous. Differences in diagnostic pathways, organisational aspects, and regional settings may lead to delays in treatment access. This study aimed to analyse these issues and to describe possible shared strategies to improve the use of immunotherapy in AGC in Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>The analysis was performed in two steps. First, a focus group comprising 13 oncologists and pathologists from 5 national reference centres was organised to collect information on the use of immunotherapy biomarker tests and the main barriers encountered in daily practice. Based on the topics emerging from this discussion, a second step was conducted using a consensus questionnaire. The questionnaire was sent to a multidisciplinary group composed of 19 oncologists, pathologists, surgeons, pharmacists, and endoscopists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Several common problems were reported during the focus group discussion. These included delays in biomarker testing, differences in pre-analytical procedures among centres, the absence of shared quality indicators, and difficulties in tracking tissue samples, especially when samples were sent from outside hospitals. In addition, limited interaction among different specialists was frequently mentioned. The results of the questionnaire indicated a high level of agreement on several proposed actions, such as the evaluation of regional differences, the use of organisational models already adopted in some Italian oncology networks, the introduction of new biomarkers together with dedicated training activities, and the use of digital tools to support the discussion of complex cases. All survey items reached the predefined consensus threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified several organizational and diagnostic challenges affecting the implementation of immunotherapy in AGC. Participants highlighted a number of potential priorities for improvement, including optimization of diagnostic workflows, stronger multidisciplinary collaboration, and greater coordination across centres. These findings may inform future initiatives aimed at reducing variability in clinical practice and supporting equitable access to innovative treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01557-0","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:17Z","timestamp":1788438977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers and Priorities for Immunotherapy Implementation in Advanced Gastric Cancer: Findings from a Two-Phase Qualitative Study"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-7837","authenticated-orcid":false,"given":"Angela","family":"Ragonese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Costanza","family":"Aquilano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana","family":"Arborea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Castri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Panarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pochettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sciattella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MAGIC Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Caira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Cervi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cioce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Dalia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Scatolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1557_CR1","unstructured":"International Agency for Research on Cancer. (2023). Stomach cancer fact sheet (GLOBOCAN 2022). Global Cancer Observatory. Retrieved June 30, 2025, from https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/7-Stomach-fact-sheet.pdf"},{"key":"1557_CR2","unstructured":"Associazione Italiana di Oncologia Medica (AIOM), & Associazione Italiana Registri Tumori (AIRTUM). (2024). I numeri del cancro in Italia. https:\/\/www.aiom.it\/i-numeri-del-cancro-in-italia\/"},{"issue":"3","key":"1557_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0759","volume":"86","author":"H Yuan","year":"2025","unstructured":"Yuan H, Bao M, Chen M, Fu J, Yu S. Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review. Br J Hosp Med. 2025;86(3):1\u201324. https:\/\/doi.org\/10.12968\/hmed.2024.0759.","journal-title":"Br J Hosp Med"},{"key":"1557_CR4","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690.","journal-title":"N Engl J Med"},{"key":"1557_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727\u201330. https:\/\/doi.org\/10.1038\/s41586-021-04161-3.","journal-title":"Nature"},{"key":"1557_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1557_CR8","doi-asserted-by":"publisher","first-page":"LBA4007","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4007","volume":"37","author":"J Tabernero","year":"2019","unstructured":"Tabernero J, Van Cutsem E, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37:LBA4007. https:\/\/doi.org\/10.1200\/JCO.2019.37.18_suppl.LBA4007.","journal-title":"J Clin Oncol"},{"key":"1557_CR9","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-20-2790","volume":"27","author":"M Lei","year":"2021","unstructured":"Lei M, Siemers NO, Pandya D, Chang H, Sanchez TK, Harbison CT, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 ipilimumab in gastric cancer\/gastroesophageal junction cancer. Clin Cancer Res. 2021;27:3926\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2790.","journal-title":"Clin Cancer Res"},{"key":"1557_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","volume":"27","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, et al. Efficacy of pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with programmed death ligand 1 combined positive score \u2265 10. Clin Cancer Res. 2021;27:1923\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2980.","journal-title":"Clin Cancer Res"},{"key":"1557_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/curroncol29030131","volume":"29","author":"A H\u00f6gner","year":"2022","unstructured":"H\u00f6gner A, Moehler M. Immunotherapy in gastric cancer. Curr Oncol. 2022;29:1559\u201374. https:\/\/doi.org\/10.3390\/curroncol29030131.","journal-title":"Curr Oncol"},{"key":"1557_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041054","volume":"14","author":"S Takei","year":"2022","unstructured":"Takei S, Kawazoe A, Shitara K. The new era of immunotherapy in gastric cancer. Cancers (Basel). 2022;14:1054. https:\/\/doi.org\/10.3390\/cancers14041054.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1557_CR13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(7):1470\u201391. https:\/\/doi.org\/10.1200\/JCO.22.02331.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1557_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10120-024-01500-x","volume":"27","author":"HD Kim","year":"2024","unstructured":"Kim HD, Shin J, Song IH, et al. Discordant PD-L1 results between 28\u20138 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy. Gastric Cancer. 2024;27(4):819\u201326. https:\/\/doi.org\/10.1007\/s10120-024-01500-x.","journal-title":"Gastric Cancer"},{"issue":"4","key":"1557_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","volume":"25","author":"J Yeong","year":"2022","unstructured":"Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25(4):741\u201350. https:\/\/doi.org\/10.1007\/s10120-022-01301-0.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1557_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4143\/crt.2019.718","volume":"52","author":"Y Park","year":"2020","unstructured":"Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, et al. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res Treat. 2020;52(3):661\u201370. https:\/\/doi.org\/10.4143\/crt.2019.718.","journal-title":"Cancer Res Treat"},{"issue":"4","key":"1557_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41379-019-0372-z","volume":"33","author":"NL Lawson","year":"2020","unstructured":"Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol. 2020;33(4):518\u201330. https:\/\/doi.org\/10.1038\/s41379-019-0372-z.","journal-title":"Mod Pathol"},{"issue":"5","key":"1557_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.32074\/1591-951X-803","volume":"114","author":"L Mastracci","year":"2022","unstructured":"Mastracci L, Grillo F, Parente P, Gullo I, Campora M, Angerilli V, et al. PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. Pathologica. 2022;114(5):352\u201364. https:\/\/doi.org\/10.32074\/1591-951X-803.","journal-title":"Pathologica"},{"issue":"2","key":"1557_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.32074\/1591-951X-836","volume":"115","author":"V Angerilli","year":"2023","unstructured":"Angerilli V, Fassan M, Parente P, Gullo I, Campora M, Rossi C, et al. A practical approach for PD-L1 evaluation in gastroesophageal cancer. Pathologica. 2023;115(2):57\u201370. https:\/\/doi.org\/10.32074\/1591-951X-836.","journal-title":"Pathologica"},{"issue":"5","key":"1557_CR20","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.modpat.2023.100154","volume":"36","author":"ME Robert","year":"2023","unstructured":"Robert ME, R\u00fcschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, et al. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Mod Pathol. 2023;36(5):100154. https:\/\/doi.org\/10.1016\/j.modpat.2023.100154.","journal-title":"Mod Pathol"},{"key":"1557_CR21","unstructured":"SIAPEC. (2015). Raccomandazioni per la tracciabilit\u00e0, raccolta, trasporto, conservazione e archiviazione di cellule e tessuti per indagini diagnostiche di Anatomia patologica. Retrieved from https:\/\/www.siapec.it\/wp-content\/uploads\/2022\/01\/Linee-Guida-tracciabilita-Raccolta-Trasporto-Conservazione-e-Archiviazione-di-cellule-e-tessuti-per-indagini-diagnostiche-di-Anatomia-patologica.pdf."},{"key":"1557_CR22","unstructured":"AIOM-SIAPEC. (2017). Raccomandazioni per la determinazione di PD\u2011L1 in oncologia: aspetti pre-analitici, analitici e interpretativi. AIOM-SIAPEC. https:\/\/www.siapec.it\/2017\/10\/26\/raccomandazioni-siapec-aiom-per-la-valutazione-del-pd-l1\/"},{"issue":"10","key":"1557_CR23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"1557_CR24","unstructured":"Rete Oncologica Piemonte e Valle d\u2019Aosta. (2021) http:\/\/www.reteoncologica.it\/images\/stories\/news_in_home\/Molecular_tumor_board\/DD_1304_del_14_09_2021_nomina_componenti_MTB.pdf"},{"key":"1557_CR25","unstructured":"Regione Lombardia. (2023, 6 novembre). Deliberazione n.\u202fXII\/2442 \u2013 Sviluppo della rete regionale per la diagnostica molecolare oncologica e istituzione del Molecular Tumor Board Regionale (MTB-R). Bollettino Ufficiale della Regione Lombardia, Serie Ordinaria n.\u202f45. https:\/\/www.regione.lombardia.it\/wps\/portal\/istituzionale\/HP\/istituzione\/Giunta\/sedute-delibere-giunta-regionale\/DettaglioDelibere\/delibera-2442-legislatura-12"},{"issue":"2","key":"1557_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","volume":"24","author":"S Bellino","year":"2024","unstructured":"Bellino S, La Salvia A. The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making. Drugs R D. 2024;24(2):123\u20137. https:\/\/doi.org\/10.1007\/s40268-024-00478-2.","journal-title":"Drugs R D"},{"key":"1557_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chbr.2022.100206","volume":"7","author":"M-J Wu","year":"2022","unstructured":"Wu M-J, Zhao K, Fils-Aim\u00e9 F. Response rates of online surveys in published research: a meta-analysis. Comput Hum Behav Rep. 2022;7:100206. https:\/\/doi.org\/10.1016\/j.chbr.2022.100206.","journal-title":"Comput Hum Behav Rep"},{"issue":"5","key":"1557_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","volume":"24","author":"B Schoemig-Markiefka","year":"2021","unstructured":"Schoemig-Markiefka B, Eschbach J, Scheel AH, Pamuk A, Rueschoff J, Zander T, et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer. 2021;24(5):1115\u201322. https:\/\/doi.org\/10.1007\/s10120-021-01195-4.","journal-title":"Gastric Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01557-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01557-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01557-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:18Z","timestamp":1788438978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01557-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01557-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required because this study involved only expert participants acting in their professional roles and did not include patients, clinical data, or identifiable personal information.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing financial or non-financial interests related to this work.","order":4,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"208"}}